Willingness to Pay for Innovative Oncology Treatments
By Staff Writer
March 16, 2024
Introduction
Cancer remains a significant global public health concern, with approximately 18.1 million new cases and 9.6 million deaths reported worldwide in 2018. Access to innovative oncology treatments is crucial in improving patient prognosis and quality of life. However, the high cost of these treatments often poses a barrier, particularly in lower-middle-income countries like Malaysia. This article explores the willingness of Malaysians to pay for these innovative treatments and how this information can be used to shape more sustainable funding solutions.
The Cost of Oncology Treatment
The financial burden of cancer treatment has seen a dramatic increase over the years. In many instances, the high cost of new oncology medicines that could potentially improve survival rates renders them unaffordable. Consequently, they are not listed in the Ministry of Health Malaysia Formulary. The financial strain often forces patients to pay out-of-pocket to access these new treatments, leading to potential economic hardships.
The Funding Challenge and Need for Innovative Solutions
In Malaysia, several foundations and non-governmental agencies occasionally provide funding assistance for cancer therapies. However, these funds are often insufficient, posing a barrier to early access to innovative oncology medicine. Therefore, there is a pressing need for innovative funding mechanisms involving multiple parties, such as healthcare providers, pharmaceutical companies, patients, non-government organisations, and other funding bodies.
Willingness to Pay for Innovative Oncology Treatments
A recent study sought to determine whether Malaysians are willing to pay for innovative oncology medicines and the amount they would be willing to pay for early access to treatment. The research was done in three hospitals in Malaysia, and also online from January 2021 to January 2022. Participants were given three hypothetical scenarios where they had to decide how much they would be willing to pay for a new diabetes medicine (IDM), a one-time payment for a new cancer medicine (IOMO), and an annual insurance premium for access to new cancer medicines (IOMI).
Table 1. Mean Willingness to Pay Amount.
The results revealed that on average, for the first model (IDM), people were willing to pay around MYR134.06 per month. The study found that older individuals and those from Sabah/Sarawak were willing to pay a little more. Also, people with higher incomes (over MYR10,001) were willing to pay significantly more.
For the second model (IOMO), the average amount people were willing to pay was MYR279.10 per dose. Here, people with higher incomes again were willing to pay more, and married individuals also tended to pay more.
For the third model (IOMI), the average amount people were willing to pay was MYR150.09 per year. In this case, only those with higher incomes were willing to pay more.
Implications and Conclusion
The results from this study can help shape collaborative funding mechanisms for cancer care in Malaysia. It is essential to introduce appropriate financial screening in public hospitals to categorise patients based on their financial hardship and channel them to suitable financial assistance. Moreover, the results underscore the need for more education and marketing initiatives to highlight the benefits of medical and health insurance, especially for covering innovative cancer medicine.
🚀 Is Europe poised to reclaim its leadership in life sciences by 2030?
The European Commission has unveiled a game-changing strategy aimed at transforming the EU into the world’s leading hub for life sciences, tackling critical challenges in health, biotechnology, and sustainability. With strategic investments and reforms, this initiative promises to bridge the innovation gap and enhance public health outcomes across the continent.
Curious about how these plans will impact the life sciences landscape? Explore the full insights of this exciting strategy!
🔍 Are we truly getting the full story on high-cost medications like ticagrelor?
A recent BMJ investigation has raised alarm bells over the integrity of data from pivotal studies on AstraZeneca’s ticagrelor, revealing significant misreporting and missing data that may undermine its clinical benefits. This exposes critical implications for health economics, regulatory oversight, and market access.
Curious about how these findings could reshape perceptions of drug efficacy and safety? Dive into the full article to uncover the truth behind the numbers.
🌍 Are we overlooking the power of self-care in Europe’s public health strategy?
The rise of self-care public health is reshaping how minor ailments are managed across the continent, leading to remarkable economic and productivity benefits. With annual savings of €36 billion and lifestyle improvements for consumers, self-care is proving to be a game-changer for healthcare systems.
Explore how embracing self-care can alleviate pressure on healthcare providers and enhance individual well-being. Dive into the full article to discover the implications for health economics and public policy!
#SyenzaNews #HealthEconomics #HealthcarePolicy
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
